• Delivered on key strategic milestones, including commercial agreement with IMV Technologies
• Commenced Phase 2 blood platelet trials with U.S. Military, generating civilian interest
• Guardion cryopreservation freezer unit delivered and deployed in the U.S.

Vitrafy Life Sciences Limited (ASX: VFY) has delivered on key strategic milestones in the first half of FY26. The company executed a strategic commercial agreement with IMV Technologies, a global leader in animal health and assisted reproductive technologies, to co-develop a market-ready solution. This 12-month, revenue-generating agreement has the potential to lead to a long-term commercial partnership. Vitrafy also commenced Phase 2 blood platelet trials with the U.S. Military, generating significant civilian interest for the technology. An important operational milestone was the delivery and deployment of the first Guardion cryopreservation freezer unit in the U.S., with a further four units currently in production to support near-term commercial opportunities. Vitrafy's U.S. go-to-market commercialization footprint has been expanded, with key sales, marketing, and commercial operations appointments, and the establishment of a U.S. headquarters in Irvine, California. The company continues to progress its pipeline across animal health, blood and blood products, and cell and gene therapies, leveraging its innovative cryopreservation ecosystem.

Vitrafy expects up to $0.9 million in revenue from the commercial agreement with IMV Technologies over the 12-month term. The company also anticipates a further $1.6 million in grant funding over the balance of calendar 2026.

Vitrafy is focused on executing its clear, milestone-driven roadmap to unlock and accelerate commercial adoption across unregulated and regulated markets. Key upcoming milestones include the initial results from the Phase 2 blood platelet studies in the second half of FY26, the establishment of U.S. manufacturing capability in Q4 FY26, and the launch of an integrated PR, digital, and conference campaign program in Q3 FY26 to drive brand awareness and generate leads.